Final treatment outcomes of multidrugand extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens

European Respiratory Journal

Volumn 50, Issue 5, 2017, Pages

  Kuksa, Liga ^a   Barkane, Linda ^a   Hittel, Norbert ^b   Gupta, Rajesh ^c  

^a RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^b Otsuka Novel Products GmbH   (Germany)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; BEDAQUILINE; CAPREOMYCIN; CILASTATIN; CLAVULANIC ACID; DELAMANID; ETHAMBUTOL; IMIPENEM; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TERIZIDONE; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; LATVIA; LETTER; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG ADULT; ADOLESCENT; DRUG EFFECT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; LATVIA; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 85034955261     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01105-2017     Document Type: Letter

References (16)

1. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2017. Stockholm, European Centre for Disease Prevention and Control, 2017.
2. Miller TL, Cirule A, Wilson FA, et al. The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia. Cost Eff Resour Alloc 2013; 11: 9.
3. Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs 2015; 75: 91-100.
4. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3: e466.
5. World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. WHO/HTM/TB/2014.23. Geneva, World Health Organization, 2014.
6. Latvia-Ministry-of-Health. National TB treatment guidelines, Latvia. Riga, Latvia, National TB Programme, 1997.
7. World Health Organization. Treatment of Tuberculosis: Guidelines. 4th Edn. WHO/HTM/TB/2009.420. Geneva, World Health Organization, 2009.
8. Tadolini M, Garcia-Prats AJ, D'Ambrosio L, et al. Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. Eur Respir J 2016; 48: 938-943.
9. Banerjee R, Allen J, Westenhouse J, et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin Infect Dis 2008; 47: 450-457.
10. Kuksa L, Riekstina V, Leimane V, et al. Multi-and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action 2014; 4: Suppl. 2, S47-S53.
11. Falzon D, Schuenemann HJ, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1602308.
12. Otsuka Pharmaceutical. Progress in Otsuka's FighTBack Initiative. Presented at the Working Group on New TB Drugs (WGND) Meeting. Liverpool, UK, October 2016. www.newtbdrugs.org/sites/default/files/meetings/files/08-Otsuka%20Update%20for%20WGND%20meeting%20Oct%202016%20FINAL.pdf Date last accessed: September 04, 2017.
13. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160.
14. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 2013; 41: 1393-1400.
15. Hafkin J, Hittel N, Martin A, et al. Early outcomes in MDR and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J 2017; 41: 1700311.
16. Gupta R, Wells CD, Hittel N, et al. Delamanid in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2016; 20: Suppl. 1, S33-S37.